The Belgian ImmunoTOXicity Board provides multidisciplinary advice on safety and side effects of immune checkpoint inhibitors and T-cell engagers.

Cases can be submitted here. Submission to BITOX does not replace the obligation to report rare or unexpected adverse events to the FAMHP.

Validated cases are reviewed twice weekly and discussed on the first and third Monday of each month via Teams. After submission, you will receive an invitation link for the next meeting. Meeting dates are available here.